Carlsmed (CARL) vs Senseonics (SENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Senseonics (SENS) has outperformed Carlsmed (CARL) over the past year, gaining 49.9% versus a gain of 39.5%. Carlsmed is the larger company by market cap ($477.4 million vs $439.3 million), about 1.1 times the size. Carlsmed converts more of its revenue into profit, with a net margin of -58.7% versus -196.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CARL | SENS |
|---|---|---|
| Share price | $17.42 | $8.02 |
| Market cap | $477.38M | $439.34M |
| 1-day change | +1.16% | -9.94% |
| YTD return | +41.05% | +45.29% |
| 1-year return | +39.47% | +49.91% |
| 5-year return | — | -87.59% |
| EPS (TTM) | $-1.13 | $-2.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $50.51M | $35.26M |
| Revenue growth (YoY) | +85.94% | +56.89% |
| Net income (latest FY) | $-29.63M | $-69.10M |
| Gross margin | 75.31% | 44.71% |
| Operating margin | -60.53% | -193.83% |
| Net margin | -58.67% | -195.99% |
| 52-week high | $19.15 | $13.98 |
| 52-week low | $8.50 | $4.79 |
| Distance from 52-week high | -9.05% | -42.62% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +26.29% | +88.03% |
| Average volume | 112.80K | 821.73K |
| Shares outstanding | 27.40M | 54.78M |
| Employees | 127 | 130 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SENS has outperformed CARL by 10.4 percentage points over the past year.
- Carlsmed is more profitable, keeping -58.7 cents of every revenue dollar as net income versus -196.0 cents for Senseonics.
- Carlsmed grew revenue faster in its latest fiscal year (+85.94% vs +56.89%).
About Carlsmed
CARL stock →Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Health Care · Medical/Dental Instruments · 127 employees
About Senseonics
SENS stock →Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
Health Care · Medical/Dental Instruments · 130 employees
CARL vs SENS FAQ
Which is bigger, Carlsmed or Senseonics?
Carlsmed (CARL) is larger, with a market capitalization of $477.38M compared with $439.34M for Senseonics (SENS).
Which stock has performed better over the past year, CARL or SENS?
SENS returned +49.91% over the past 12 months, compared with +39.47% for CARL (price return, excluding dividends). Past performance does not predict future results.
Are Carlsmed and Senseonics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.